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Methicillin-resistant Staphylococcus aureus (MRSA) is a serious public health problem 
nationwide, threatening to develop into an epidemic.  Many of these patients are presenting to 
their primary care clinics with skin and soft tissue infections (SSTIs).  The CDC has reported 
that in 2005, MRSA was responsible for an estimated 94,000 life-threatening infections and 
16,650 deaths.  The purpose of this study is to estimate the incidence of CA-MRSA within a 
specific family practice in Florida and to identify epidemiologic factors, classify antibiotic 
susceptibility patterns, and evaluate patient education in regard to disease management and 
prevention.  
This study was a descriptive, epidemiologic, three-year retrospective medical record 
review of all wound cultured skin and soft tissue infections that presented to a family practice 
between January 2007 and December 2009.    
Sixty-two medical records met the inclusion and exclusion criteria for the study.  Of these 
62 SSTIs, 44 cultures grew one or more bacterial organisms.  The incidence of CA-MRSA was 
66% (n=29).   The mean age of those with CA-MRSA was 40 years old, with a range from 7 to 
90 years old.  Sixty-two percent (n=18) were male and 38% (n=11) were female; additionally 
69% (n=20) lived within a 10 mile radius from the family practice, while 31% (n=9) lived in a 
surrounding suburb. The most frequent race was Caucasian 83% (n=24), with African American 
at 10% (n=3) and Hispanics 7% (n=2).  Risk factors associated with CA-MRSA was obesity 
41% (n=10), diabetes mellitus 24% (n=7), and a previous history of MRSA infection 24% (n=7).  
Skin and soft tissue infections were diagnosed as either an abscess 62% (n=18), boil 24% (n=7), 
pustule 10% (n=3), or cellulitis 4% (n=1).  CA-MRSA isolates were susceptible to trimethoprim-
sulfamethoxazole 100% (n=29), doxycycline 93% (n=27), and rifampin 100% (n=14).  
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Clindamycin susceptibility was 65% (n=15) with resistance at 30% (n=7) and 5% (n=1) 
intermediate.  Both cephalexin and erythromycin were 100% resistant.  Documentation in the 
medical record on wound care was found in 45% (n=13) of the records.   
The incidence of CA-MRSA SSTI was 66%, which identifies this suburban community 
at high risk for this bacterial infection.  Risk factors associated with CA-MRSA included obesity 
(BMI >30), history of previous MRSA infection, and diabetes mellitus.  There were no clinical 
characteristics that helped distinguish MRSA infection from other bacterial SSTIs.  Most SSTI 
were treated with incision and drainage and a susceptible antibiotic.  Judicious use of antibiotics 
not only provides appropriate treatment, but is also critical in prevention of antibiotic resistance.  











I wish to dedicate this thesis to my husband Dave and two daughters, Amanda and Megan.  











I would like to acknowledge that this thesis could not have been written without my 
thesis committee members who not only served as my supervisors but also encouraged and 
challenged me through my academic program. It is a pleasure to specifically thank Dr. Elizabeth 
Rash, who not only was my professor but also my thesis chair who invested time in my academic 
and professional growth.  I also want to thank Dr. Christopher Blackwell who early in my studies 
supported my research interests.  Lastly, I owe my deepest gratitude to Dr. Addam Masri, who 
has been my mentor, colleague, and advisor for many years.  He made what seemed impossible, 
possible, and with his support was able to continue working and pursuing doctoral studies.    
  
vii 
TABLE OF CONTENTS 
LIST OF TABLES   ......................................................................................................................... xi
CHAPTER 1: INTRODUCTION   ................................................................................................... 1
Background of the Problem   ........................................................................................................ 2
Rising Incidence of CA-MRSA SSTI   ..................................................................................... 2
Growing Antibiotic Resistance   ............................................................................................... 3
Assessment of Need for Study   .................................................................................................... 4
Varying Standards of Treatment for SSTIs   ............................................................................ 5
Specific Aim of the Project   ......................................................................................................... 6
Study Objectives   ......................................................................................................................... 6
Research Questions   ..................................................................................................................... 7
Conceptual and Operational Definition of Variables   .................................................................. 7
Adverse Event (AE)   ................................................................................................................ 8
Antibiotic Susceptibility   ......................................................................................................... 8
Community-Acquired MRSA (CA-MRSA)   ........................................................................... 9
Demographic   ........................................................................................................................... 9
Iatrogenic High Risk Invasive Procedure   ............................................................................... 9
Incidence of CA-MRSA   ....................................................................................................... 10
Patient Clinical Characteristics   ............................................................................................. 10
Patient Risk Factor   ................................................................................................................ 10
Recurrent Skin Infection   ....................................................................................................... 11
Skin and Soft Tissue Infection (SSTI)   .................................................................................. 11
Wound Care   .......................................................................................................................... 11
  
viii 
Importance of the Study and Knowledge to be Gained   ............................................................ 12
Outline of the DNP Study   ......................................................................................................... 12
CHAPTER 2: SYNTHESIS OF THE RESEARCH EVIDENCE   ................................................ 14
Epidemiology   ............................................................................................................................ 14
Prevalence of CA-MRSA   ......................................................................................................... 16
Healthcare Costs Associated with CA-MRSA   ......................................................................... 17
Antibiotic Resistance – A Growing Concern  ............................................................................ 18
Implications for Research   ......................................................................................................... 19
CHAPTER 3: STUDY DESIGN   .................................................................................................. 21
Strengths and Limitation of Proposed Design   .......................................................................... 21
Setting   ....................................................................................................................................... 22
Sample  ....................................................................................................................................... 22
Strategies for Gaining Access to Medical Records   ................................................................... 23
Exclusion Criteria   ..................................................................................................................... 23
Inclusion Criteria   ...................................................................................................................... 23
Institutional Review Approval   .................................................................................................. 24
HIPAA Guidelines and Confidentiality   .................................................................................... 24
Study Instruments and Tools   .................................................................................................... 24
Study Procedures   ...................................................................................................................... 25
Study Protocol/Procedures   ........................................................................................................ 25
Data Collection Tool   ................................................................................................................. 27
Data Analysis   ............................................................................................................................ 27
Limitations of the Study  ............................................................................................................ 28
  
ix 
CHAPTER 4: RESULTS   .............................................................................................................. 30
Description of the Sample   ......................................................................................................... 30
CHAPTER 5: CONCLUSION   ..................................................................................................... 39
Discussion   ................................................................................................................................. 39
Incidence of CA-MRSA   ....................................................................................................... 40
Demographic Characteristics of CA-MRSA SSTI   ............................................................... 40
Clinical Characteristics of CA-MRSA SSTI   ........................................................................ 43
Risk Factors of CA-MRSA SSTI   .......................................................................................... 44
Antibiotic Susceptibilities of CA-MRSA SSTI Isolates   ....................................................... 44
Patient Education and Documentation   .................................................................................. 46
Limitations of Study   ................................................................................................................. 46
Conclusion   ................................................................................................................................ 48
Implications for Nursing Practice   ............................................................................................. 49
Implications for Education   ........................................................................................................ 50
Recommendations for Future Research   .................................................................................... 51
APPENDIX A: SPSS VARIABLE KEY CODE  .......................................................................... 52
APPENDIX B: COLLECTION TOOL   ........................................................................................ 56
APPENDIX C: OUTPATIENT MANAGEMENT OF SKIN AND SOFT TISSUE 
INFECTIONS IN THE ERA OF COMMUNITY-ASSOCIATED MRSA   ..................... 60
APPENDIX D: OPTIONS FOR EMPIRIC OUTPATIENT ANTIMICROBIAL TREATMENT 
OF SSTIS WHEN MRSA IS A CONSIDERATION   ....................................................... 62
APPENDIX E: SUMMARY OF ARTICLES REVIEWED ON CA-MRSA   .............................. 65
APPENDIX F: CODE TABLE OF REVIEWED ARTICLES  ..................................................... 68
  
x 
APPENDIX G: LOG FORM   ........................................................................................................ 70
APPENDIX H: PATIENT EDUCATION PAMPHLET   .............................................................. 72
APPENDIX I: IRB APPROVAL  .................................................................................................. 74




LIST OF TABLES 
Table 1. Characteristics of Isolated Organisms   ............................................................................ 31
Table 2. Demographics of Culture Positive SSTI CA-MRSA   ..................................................... 32
Table 3. Clinical Risk Factors Associated with Culture Positive CA-MRSA   .............................. 34
Table 4. Clinical Characteristics Associated with Culture Positive MRSA SSTI   ........................ 36




CHAPTER 1: INTRODUCTION 
Methicillin-resistant Staphylococcus aureus (MRSA) has become a major public health 
concern in the last 10 years.  This type of infection was traditionally acquired in hospitalized, 
immuno-compromised, severely ill, or chronically ill patients, but now it is increasing in the 
community among people without these health risks (Ellis et al., 2007).  The global 
epidemiology of MRSA continues to change, as recent studies have demonstrated that MRSA 
has diverged into two separate categories known as community-acquired MRSA (CA-MRSA) 
and healthcare-associated MRSA (HA-MRSA) (Cohen, 2007a; Elston, 2007; Farley, 2008).  
HA- MRSA has more antibiotic-resistant genes than CA-MRSA; however, CA-MRSA may be 
more virulent, more frequently causing serious and fatal infections in healthy individuals.  
Currently, up to 25% of MRSA with onset in the hospital or community is due to CA-MRSA 
USA300 (Klevens RM, 2006; Liu C, 2008; Popovich, 2008).   
The clinical distinctions between HA-MRSA and CA-MRSA are becoming blurred, with 
both strains causing disease in community and healthcare settings.  Though distinct, these strains 
are highly virulent and are increasing in incidence.  In particular, the new strain of CA-MRSA 
has become a serious public health problem nationwide, beginning to reach epidemic proportions 
(Hawkes et al., 2007; Hinckley & Allen, 2008; Klevens et al., 2007).  Researchers at the Centers 
for Disease Control and Prevention have reported that MRSA was responsible for an estimated 
94,000 life-threatening infections and 18,650 deaths in 2005 (Klevens et al., 2007).  Klevens 
(2007) concluded that in the same year, roughly 16,000 people in the U.S. died from Acquired 
Immunodeficiency Syndrome (AIDS).   
The impact of MRSA extends beyond afflicted patients to include clinicians, insurance 
industries, pharmaceutical companies, federal and state governmental agencies, healthcare 
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facilities, and society in general.  Each of these are stakeholders who have an interest in 
implementing programs that treat MRSA in a more efficacious, timely, and cost-effective 
manner.  Medical costs due to MRSA infections are rising rapidly (Scott et al., 2005; Shorr, 
2007).  This is due to the many potential problems associated with treatment failure, including 
additional outpatient office visits, hospitalizations often requiring isolation, increased lab testing 
and surveillance, longer length of inpatient stay, more aggressive surgical intervention, and 
poorer patient outcomes.  Implementing a program that treats MRSA more effectively and 
rapidly would make a significant impact on reducing cost and improving patient outcomes.  It 
would lessen the risk to society by reducing carriage rates and preventing transmission of MRSA 
infection to others in the community (Abrahamian & Shroff, 2007).   
Background of the Problem 
Rising Incidence of CA-MRSA SSTI 
Several problems related to Staph-resistant infections have been identified.  First, there 
has been a dramatic increase in the number of patients who have presented to outpatient offices 
and emergency rooms with skin and soft tissue infections (SSTIs) that have cultured positive 
with CA-MRSA ("CA-MRSA shown to be an emerging problem," 2008). Unfortunately, most 
purulent skin infections are not routinely cultured.  Rather, they are frequently treated 
empirically with antibiotics, which are ineffective against MRSA and can compound antibiotic 
resistance.   
          Another problem is that MRSA is affecting pediatric and adult populations that are 
relatively healthy, which until recently were an uncommon occurrence (Hinckley & Allen, 
2008).  Furthermore, the progression of the MRSA infection does not typify the established 
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characteristics associated with patients known to have hospital-acquired MRSA.  The circulation 
of CA-MRSA strains in hospitals has already been described, with several reports suggesting that 
CA-MRSA may be replacing HA-MRSA strains, with potentially catastrophic consequences.  
CA-MRSA strains are usually considered to be more virulent than HA-MRSA, leading to an 
important problem in terms of morbidity and mortality if they reach the hospital population 
(Patel, 2008; Popovich, 2008; Seybold et al., 2006).  
Because of these factors, MRSA is spreading rapidly and becoming a serious healthcare 
problem (Klevens et al., 2007).  National awareness of this problem has been dramatized by 
reports of young athletes and other healthy adults dying from CA-MRSA.  The threat of 
transmission has led to canceled sporting events and the closing of schools (C. J. Weber, 2008).  
There are conflicting expert opinions related to the management and treatment of SSTI 
that need further investigation.  Some practitioners treat SSTI with incision and drainage only, 
without prescribing antibiotics (Fridkin et al., 2005; Lee et al., 2004).  Others start empiric 
antibiotics without first obtaining a wound culture for sensitivity testing (Cohen, 2007b; Miller & 
Spellberg B., 2004).  Consistency in treatment approach is lacking.   
Growing Antibiotic Resistance 
Antibiotic resistance occurs when bacteria change in some way that reduces or eliminates 
the effectiveness of drugs, chemicals, or other agents designed to cure or prevent infections 
(Merriam-Webster, 2009).  How do bacteria become resistance to antibiotics?  The CDC states: 
Antibiotics kill or inhibit the growth of susceptible bacteria, but sometimes some 
bacteria can survive and multiply and replace all the bacteria that were killed off.  
Exposure to antibiotics therefore provides selective pressure, which makes the 
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surviving bacteria more likely to be resistant.  In addition, bacteria that were at one time 
susceptible to an antibiotic can acquire resistance through mutation of their genetic 
material or by acquiring pieces of DNA that code for the resistance properties from 
other bacteria (Center for Disease Control and Prevention, 2010).    
Antibiotic-resistant infections have produced a significant increase in morbidity and 
mortality for individuals that contract these illnesses.  At best, intermediate resistant antibiotics 
promote a slower response and delay in achieving effective treatment; at worst, they may 
produce increased antibiotic resistance, additional outpatient office visits, hospitalizations, loss 
of work or school, outright treatment failure, and death (Gorwitz, Jernigan, Powers, Jernigan, & 
Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the 
Community, 2006).  
Assessment of Need for Study    
In Florida, outpatient reporting of diagnosed cases of CA-MRSA to county health 
departments is not mandatory.  In fact, there are only two instances when MRSA is required to 
be reported to the local health department: when there is an outbreak of MRSA infections or 
when there has been a death associated with MRSA infection (Sanderson, 2008).  Only one 
report discussing the rise of MRSA in the state could be found.  Based on statistics provided by 
Quest Diagnostic Laboratory between 2003 and 2006, the Department of Health (DOH) reported 
that the prevalence of MRSA is increasing (Sanderson, 2008).  This laboratory, which serves 
clinics and physician offices, provided the Department of Health DOH with all of its S. aureus 
culture results for the entire state over this four-year period, with incidence broken down by 
county.  The results demonstrated an increase from 8,299 isolates in 2003 to 48,953 isolates for 
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2006.  More specifically, and more ominously, the proportion of these isolates that was 
specifically recognized as MRSA rose from 35% in 2003 to 50% in 2006 (Sanderson, 2008). 
Varying Standards of Treatment for SSTIs 
Current standards for treatment of skin and soft tissue infections in an outpatient setting 
include incision and drainage with subsequent antimicrobial therapy prescribed empirically 
(Cohen, 2007a; Elston, 2007; Fleming, Brown, & Tice, 2006; Fridkin et al., 2005).  However, 
many of the antibiotics being prescribed are ineffective against MRSA.  As a result of this, 
researchers are endorsing the importance of obtaining wound cultures for all purulent or incised 
and drained SSTIs (Abrahamian & Shroff, 2007; Pallin et al., 2008).  Identifying the specific 
microorganism causing STTIs using a wound culture would provide essential information 
needed by the clinicians to maximize antimicrobial potency (Cohen, 2007a; Elston, 2007; Farley, 
2008; Fleming et al., 2006; Moran et al., 2006).   
The Centers for Disease Control and Prevention (CDC) has developed a treatment 
guideline to help direct decision making in the treatment of suspected CA-MRSA SSTI’s 
(Gorwitz et al., 2006).  Studying practice patterns to determine whether clinicians are 
incorporating current evidence-based research is imperative.  This is especially important for 
primary healthcare providers who are at the frontline and are assessing individuals with SSTI’s 
that may have contracted CA-MRSA.    
The purpose of this research is to assess and support strategic measures that improve 
identification of microorganisms resistant to conventional antimicrobial drug therapy, improve 
bacterial surveillance within communities, and reduce the spread of the infection (Bach, Steffin, 
Chhadia, Kovachevich, & Gonzalez, 2007; Pallin et al., 2008).  A description of this problem 
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within a specified population subgroup in a community might lead to improved outcomes in 
MRSA treatment due to an increase in the awareness of the problem, as well as a mobilization of 
resources needed to solve problems specific to this issue. 
Specific Aim of the Project 
 Due to emerging drug-resistant pathogens and antibiotic susceptibility, the purpose of this 
project is threefold (Owens, 2009).  The first aim is to estimate the incidence of CA-MRSA in 
cultured SSTI’s found in patients presenting to a suburban Florida family practice.  Secondly, the 
study results identify empiric antibiotic prescribing patterns for skin and soft tissue infections.  
The final aim is to identify patient demographic characteristics, risk factors, and clinical 
characteristics and evaluate patient education of this specific population that has been cultured 
positive with MRSA SSTIs.   
 Consistent identification of CA-MRSA improves laboratory epidemiological reporting 
and provides the appropriate agencies with the ability to better address these trends.  Nursing 
research that contributes to improving treatment guidelines directly impacts patient outcomes, 
one of the primary goals of the nursing discipline. 
Study Objectives 
• Determine the incidence of CA-MRSA SSTI in an outpatient family practice in Apopka, 
Florida, and improve surveillance and reporting of this emerging bacterial infection 
within that community.   
• Identify patient demographic, patient risk factors, clinical characteristics, and antibiotic 
susceptibility associated with patients that have culture positive MRSA. 
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• Determine if family practice policy change is needed for the treatment of suspected CA-
MRSA that includes recommending that purulent or incision and drained wounds have a 
culture performed on the initial visit and incorporate patient educational material aimed at 
preventing the spread of infections to others.      
Research Questions 
Question One: What is the incidence of community-acquired MRSA in cultured skin and 
soft tissue infections in a suburban Florida family practice? 
Question Two: What are the selected demographic characteristics associated with the 
culture positive CA-MRSA skin and soft tissue infections?  
Question Three: What are the selected clinical characteristics associated with the culture 
positive CA-MRSA skin and soft tissue infections? 
Question Four: What are the selected risk factors associated with the culture positive CA-
MRSA skin and soft tissue infections?   
Question Five: What are the antibiotic susceptibilities associated with the culture positive 
CA-MRSA skin and soft tissue infections? 
Question Six: How many patients diagnosed with a SSTI had education regarding wound 
care documented in their medical record?  
Conceptual and Operational Definition of Variables 
 A conceptual definition presents the abstract or theoretical meaning of the concepts being 
studied.  Operational definitions for each variable are intended to narrow the number of details 
measured by eliminating elements not relevant to the study.  These definitions specify which 
variables to study and what methods to use to study them.  Each variable is assigned a label 
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along with a list of all possible responses of the most common attributes (Oman, 2003).  Each 
variable’s level of measurement had been assigned (see Appendix A).  The responses are 
mutually exclusive so that only one answer for each item is selected on the data collection tool 
(see Appendix B). 
Adverse Event (AE) 
Conceptual: Defined as any unfavorable and unintended sign or symptom, including any 
new subjective complaint, or objectively definable illness, injury or abnormal laboratory finding, 
during the period of treatment (Oman, 2003) 
Operational: Any adverse change in health or “side effect” that occurs in a person who 
participates in a clinical trial, either while the patient is receiving the treatment or within a pre-
specified period of time after the treatment has been completed (Oman, 2003). 
Antibiotic Susceptibility 
Conceptual: Vulnerability of a specific bacterial strain to antibiotic treatment (Mayer, 
2009). 
Operational: Antibiotic susceptibility is determined using the VITEK 2 system according 
to the National Committee for Clinical Laboratory Standards guidelines and reported on the 
culture and sensitivity report.  Organism is identified and reported as “resistant,” “susceptible,” 
or of “intermediate” resistance to specific antibiotics based on the mean inhibitory concentrations 
(MIC) standards of the Clinical and Laboratory Standards Institute (Mayer, 2009). 
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Community-Acquired MRSA (CA-MRSA) 
Conceptual: An infection with a strain of Staphylococcus aureus bacteria that is resistant 
to beta-lactam antibiotics (Center of Disease Control and Prevention, 2005).  These antibiotics 
include methicillin, amoxicillin, and penicillin.  This infection is a strain from the community 
and not health-associated MRSA. 
Operational: Diagnosis of MRSA was made in the outpatient setting or by a culture 
positive for MRSA within 12 months post hospital admission.  No medical history in the past 12 
months of hospitalization, admission to a nursing home, skilled nursing facility, hospice, 
dialysis, or surgery.  No permanent indwelling catheters or medical devices that pass through the 
skin into the body (Center of Disease Control and Prevention, 2005). 
Demographic   
Conceptual: Vital and social statistics of a population (Oman, 2003). 
Operational: Age in years, gender, ethnicity, occupation, home location, and whether 
patient has health insurance (Oman, 2003). 
Iatrogenic High Risk Invasive Procedure 
Conceptual: A medical treatment, examination, or diagnostic procedure that involves 
entry into the body either by incision or by insertion of an instrument through the skin, body 
cavity, or organ prescribed by a physician (Merriam-Webster, 2009). 
Operational: A medical procedure or treatment in the previous three months that includes 
laparoscopic, endoscopic, or interventional radiologic procedure. 
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Incidence of CA-MRSA 
Conceptual: A measure of the frequency with which new cases of illness, injury,  or 
other health condition occurs among a population during a specified period (U.S. Department of 
Health and Human services, 2004). 
Operational: Incidence is the measure of the frequency with which new cases of CA-
MRSA SSTI  occurred among a population during a specified period of time (U.S. Department 
of Health and Human services, 2004) 
Patient Clinical Characteristics 
 Conceptual: A feature that helps to identify, tell apart, or describe the character of 
someone or something (Merriam-Webster, 2009).  Presence of fever, size of wound, wound 
purulence (pus), whether incision and drainage and/or, wound packing were required duration of 
symptoms before presentation and clinical diagnosis. 
Operational: Oral temperature is taken and documented in Fahrenheit degrees.  Fever is 
defined as a temperature equal to or greater than 100.4o
Patient Risk Factor 
 F.  Size of wound is measured in 
centimeters or inches.  The data collection tool documents if the wound was purulent (draining 
pus) and required incision and drainage or packing.  The duration of symptoms before 
presentation is recorded in days on the data collection tool. 
Conceptual: A characteristic, condition, or behavior that increases the possibility of 
disease or injury (Merriam-Webster, 2009).  
Operational: Document co-morbidities defined as a condition existing simultaneously 
and independent of another medical condition (Merriam-Webster, 2009):  Obesity (BMI >30), 
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immune compromised, attends daycare/child care center, diabetes or renal failure, previous 
MRSA infection in the last 12 months, surgery in the last 12 months, dialysis patient, 
hospitalization in the last 12 months, long-term care resident in the last 12 months, indwelling 
catheters, chronic skin conditions such as eczema or psoriasis, or use of IV drugs.   
Recurrent Skin Infection 
 Conceptual: Reinvasion or multiplication of a bacterial microorganism in a previously 
treated body tissue, which causes new local cellular injury, though not necessarily the same 
anatomic site or strain (Gorwitz et al., 2006). 
 Operational: A patient who has been treated with an antibiotic for a SSTI within the 
previous 60 days who presents with a recurrent skin infection. 
Skin and Soft Tissue Infection (SSTI) 
Conceptual: Invasion and multiplication of microorganisms in body tissue that causes 
local cellular injury (Merriam-Webster, 2009). 
Operational: Skin infection may include but not limited to: boil, folliculitis, 
furuncle/carbuncle, abscess, insect/spider bite, cellulitis, paronychia, or impetigo (Center of 
Disease Control and Prevention, 2005). 
Wound Care 
Conceptual: A set of instructions on how to reduce risks that can inhibit wound healing 
and enhance the healing process (Gorwitz et al., 2006). 
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Operational: Documentation of at least one of the following:  Instructions on how to 
clean and dress the wound, frequent hand washing or use of an alcohol-based hand sanitizer, or 
education on how to prevent spread of skin infection to others (Gorwitz et al., 2006). 
Importance of the Study and Knowledge to be Gained 
          There is a need for healthcare professionals, such as primary care nurse practitioners, to 
investigate the demographic and incidence of this emerging infection not only in their 
community but also within their geographic practice area.  Identifying epidemiological factors of 
patients who develop CA-MRSA is important, as clinical findings can be a key to treating 
patients correctly from the initial contact with a practitioner.  The paucity of information 
regarding the MRSA epidemic within the community should be of great concern to all healthcare 
providers.  Unaware of the potentially dramatic increase of MRSA locally, the practitioner may 
not feel compelled to stay abreast of current guidelines that would improve the efficacy of his or 
her treatment.  The purpose of this study is to estimate the incidence of CA-MRSA, identify 
clinical characteristics, risk factors, and antibiotic susceptibility, and evaluate patient education 
specifically at Central Family Practice located in the city of Apopka, Florida.   
          Establishing a clearer understanding of the incidence of CA-MRSA within the setting one 
works in, including clinical indicators for appropriate antibiotic treatment and wound culturing, 
should result in better understanding of the evolution of the disease in the community.   
Outline of the DNP Study 
 Chapter 2 is a synthesis of relevant and related research studies.  This chapter concludes 
with a summary of the research evidence and applicability that supports the proposed DNP 
research questions under study.  Chapter 3 describes the project implementation plan, which 
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includes study design, description of population, and sample method of participants, setting, and 
ethical consideration such as protection of human by the Institutional Review Board (IRB).  
Specific study procedures are outlined, which includes the use of the data collection tool and the 
statistical testing to be done.  Chapter 4 presents the findings and discusses how the data answers 
each of the research questions.  Finally, Chapter 5 is where the discussion of the findings of the 
study, which include implications for nursing and recommendations for further related projects, 




CHAPTER 2: SYNTHESIS OF THE RESEARCH EVIDENCE 
 The following chapter is a review and synthesis of the relevant and related research 
studies regarding CA-MRSA.  The project proposed in this study is aimed at estimating the 
prevalence of CA-MRSA of SSTI that are cultured in an outpatient family practice and 
identifying clinical characteristics along with antibiotic sensitivity results.  The epidemiology of 
MRSA is discussed to better understand populations at risk and this infection’s incidence.  The 
next section addresses the escalating health care costs associated with CA-MRSA and the 
growing concern of antibiotic resistance.  In conclusion, a brief summary of the implications to 
the research problem under study and the applicability to the DNP thesis is outlined.    
Epidemiology 
There are distinctly different characteristics between the strains of MRSA isolated from 
the community compared to the nosocomial strains (Grundmann, Aires-de-Sousa, Boyce, & 
Tiemersma, 2006).  These community-acquired strains often express resistance to beta-lactams 
alone, in contrast to the multidrug-resistance pattern that typifies nosocomial strains, which has 
implications for appropriate antibiotic selection in the community.  Community-acquired MRSA 
has been isolated in both children and adults, with outbreaks occurring in several discrete patient 
populations.  Identified at-risk populations include children in daycare centers, soldiers, 
intravenous drug users, prisoners, homeless persons, men who have sex with men, and 
competitive athletes (Kowalski, Berbari, & Osmon, 2005).  Common to these groups are the 
following factors that aid the spread of infection: crowding, frequent skin-to-skin contact 
between individuals, participation in activities that result in compromised skin surfaces, sharing 
of personal items that may become contaminated with wound drainage, and challenges 
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maintaining personal cleanliness and hygiene (Gorwitz et al., 2006).  Other outbreaks have 
occurred in certain ethnic groups, including Pacific Islanders, Native Americans/Alaska Natives, 
and Pacific and Canadian aboriginals (Center for Disease Control and Prevention, 2004).  
Patients present in the outpatient setting with skin and soft tissue infections (SSTIs), 
which are commonly diagnosed as furuncles, carbuncles, abscesses, or cellulitis.  At times, these 
infections can initially go unnoticed or be misdiagnosed by primary care staff.  For example, the 
sudden appearance of a raised red skin lesion causes many patients to present with complaints of 
a spider bite, even though they do not recall being bitten.  In fact, the lesion is often the 
beginning of a MRSA infection.  In contrast, presentations of severe invasive MRSA infections 
in the community requiring hospitalization have included septic arthritis, bacteremia, toxic shock 
syndrome, necrotizing fasciitis, and necrotizing pneumonia (Cohen, 2007b; Grundmann H, 
Aires-de-Sousa M, Boyce J, & Tiemersma E, 2006).  These types of infections usually require 
surgical intervention for incision and drainage, followed by a course of intravenous antibiotics.  
Being able to detect and treat infections earlier in their trajectory can result in reduced cost and 
improved patient outcomes. 
The burden of morbidity and mortality caused by MRSA is staggering.  The Centers for 
Disease Control (CDC) estimated the number of people developing a serious MRSA infection in 
2005 was about 94,360 and that 18,650 persons died during a hospital stay related to these 
serious MRSA infections (Center for Disease Control and Prevention, 2007a).  The incidence 
rate in 2005 of invasive MRSA rate was 31.8 per 100,000, and the mortality rate was 6.3 per 
100,000 patients (Klevens et al., 2007).  The Institute of Medicine estimates the annual cost of 
infections caused by antibiotic-resistant bacteria in the United States to be $4 to $5 billion 
(McGowan, 2001).   
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Prevalence of CA-MRSA 
The leading epidemiologic expert on MRSA at the Florida Health Department reports 
only one known study conducted in the state of Florida that tries to identify the prevalence of 
CA-MRSA (Sanderson, 2008).  This descriptive epidemiology study of outpatient illnesses in 
Florida, reported that those infected with CA-MRSA had risen from 35.1% in 2003 to 49.7% in 
2005 (Kolar, 2007).  Another recent study implicated CA-MRSA as the most common cause of 
community-acquired SSTIs in California (Moran et al., 2006).  An additional study found that 
CA-MRSA had exceeded 70% of all SSTIs  in Atlanta and Houston (Hawkes et al., 2007).  A 
14-year surveillance study at Driscoll Children’s Hospital in Texas reported a rapid emergence in 
the number of hospitalizations for CA-MRSA from 1990-2003 (Purcell & Fergie, 2002).  The 
same researchers analyzed the data collected from 1990-2001 and compared the data from 2002-
2003, finding that the prevalence of CA-MRSA cases rose exponentially from 0-9 per year 
before 1999, to 36 in 2000, to 459 in 2003.  The authors concluded that the rapid surge of CA-
MRSA as a cause of noninvasive and invasive infections in children started occurring in the 
1990s and has now reached epidemic proportions (Purcell & Fergie, 2005).   
The incidence of CA-MRSA in skin abscesses presenting to a pediatric emergency 
department over an 18-month period was studied.  The results of 68 patients enrolled and 
cultured identified that 85% were culture positive CA-MRSA (Magilner, 2008).  In another 
study, researchers examined the incidence of CA-MRSA in SSTI in suburban dermatology 
private practice.  The authors concluded that of 170 cultures taken, 21% were positive for CA-
MRSA (Bruce, 2008).  Lastly, an 18-month retrospective chart review between January 2004 and 
August 2005 to assess prevalence in two major military hospital emergency departments was 
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conducted.  The results found the prevalence rate of 68% of CA-MRSA in soft tissue abscesses 
(Dufresne, 2008).   
The literature review supports the escalating rates of MRSA infections in a variety of 
patient settings.  The vast majority of this literature comes from urban settings with high 
population densities.  Determining the incidence of CA-MRSA in SSTI in smaller suburban 
communities needs to be established.  
Healthcare Costs Associated with CA-MRSA   
Whereas previously most hospitalizations for MRSA were attributable to HA-MRSA,   
CA-MRSA strains are now being identified as the primary cause for hospitalization.  
Understanding the impact of MRSA is important for clinicians, hospital administrators, and 
policy makers.  Multiple studies have been conducted to measure the direct medical costs of 
MRSA infection.  This information justifies using the necessary resources to combat antibiotic 
resistance and to prevent the spread of resistant organisms.  
One study looked at the economic impact of Staphylococcus aureus infections in New 
York hospitals.  The death rate of patients admitted with MRSA was 8%, while direct medical 
costs of community-acquired infections per patient was $35,300 (Rubin et al., 1999).  Another 
cohort study of patients admitted into a teaching hospital in Boston, Massachusetts, with MRSA 
bacteremia revealed a length of stay of nine days, costing $26,424, whereas methicillin-sensitive 
Staphylococcus aureus (MSSA) required a stay of only seven days, costing $19,212 (Cosgrove et 
al., 2005).  A retrospective case control analysis comparing MSSA with MRSA infections 
revealed that the increased median hospital cost associated with MRSA was $16,575 per 




resistant nosocomial infections listed costs per admission that ranged from as low as $9,275 and 
as high as $82,020 (Scott et al., 2005).   
Antibiotic Resistance – A Growing Concern 
With the rise of infections of microorganisms resistant to conventional antimicrobial drug 
therapy, choosing the correct antibiotic for treatment is essential.  In order to more effectively 
accomplish this, some of the literature reviewed mentions or supports the use of incision and 
drainage of SSTI and also supports doing wound cultures for sensitivities (Cohen, 2007a; Delit, 
Duchin, Hofmann, & Gurmai, 2004; Elston, 2007; Fleming et al., 2006; Gorwitz et al., 2006; J. 
T. Weber, 2005).  
One prospective study of 62 children in Texas who had culture positive CA-MRSA SSTI 
concluded that incision and drainage without antibiotics was effective management for wounds  
less than five centimeters in diameter in immuno-competent children (Lee et al., 2004).  
Treatment consisted of drainage of 96% of patients and wound packing in 65%.  All children 
were treated with antibiotics; however, four of the 62 patients (6%) that received this treatment 
were subsequently admitted to the hospital at the first follow-up; these patients had been 
empirically treated with a resistant antibiotic against CA-MRSA before wound culture results 
were available (Lee et al., 2004).  Another study evaluated positive MRSA infections in 1,647 
patients in the communities of Atlanta, Baltimore, and Minnesota from 2001-2002 and found 
that between 8% and 20% were community-acquired.  The authors concluded that clinicians 
need to consider MRSA as a potential pathogen and, to prevent clinical complications, should 
obtain bacterial wound cultures and recommend surgical drainage of skin and soft tissue 
infections when feasible (Fridkin et al., 2005).   
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Guidelines of the Infectious Disease Society of American (IDSA) recommend that 
purulence containing infections should alert clinicians to suspect CA-MRSA.  They recommend 
that refractory infections that do not respond to beta-lactam antibiotics should have a wound 
culture and sensitivity done, particularly in high-risk groups (Stevens et al., 2005).  Recent health 
updates from the infectious disease task forces of several Departments of Health Services have 
released treatment guidelines to healthcare providers, stating that bacterial culture and 
antimicrobial sensitivity testing be done in all community-acquired SSTI (County of Sonoma 
Department of Health Services, 2008; Public Health Seattle & King County, 2007).  A combined 
effort between the CDC, American Medical Association and the IDSA have developed and 
recommended a treatment algorithm for outpatient management of skin and soft tissue infections 
in the era of CA-MRSA (see Appendixes B and C).  
Implications for Research  
 Several key findings of the literature synthesis have made clear some areas in need of 
further research.  A literature review matrix to organize the data extraction was created that 
included methodology study results and critique of selected research studies (see Appendix E 
and F).   
 First, the literature review indicates that there are different methods being employed by 
providers in the treatment of CA-MRSA. The CDC has created clinical guidelines that are not 
being consistently implemented. A key finding is that wound culturing of SSTIs is not routinely 
being done.  As antibiotic resistance in our society is escalating, it becomes even more important 
to understand the prevalence of MRSA infections within the communities where clinicians 
practice. This information is critical when making decisions regarding treatment of skin and soft 
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tissue infections. Secondly, the need to document the incidence of CA-MRSA for the purposes of 
surveillance and antibiotic susceptibility is another key finding in this literature review.  The 
nursing profession is expected to base their professional practice on emerging evidence from 
research; that is, nurses need to adopt an evidence-based practice (EBP).  This study should help 
facilitate examination of one suburban outpatient family practice’s current treatment of SSTI and 
associated epidemiologic factors.  Based on this study’s findings, the researcher may have 
evidence to support policy change within the practice for the treatment of SSTI, with the goal of 
enhancing patient outcomes.     
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CHAPTER 3: STUDY DESIGN 
 This study is a descriptive epidemiologic retrospective medical record review of all 
wound cultured SSTI that presented to a family practice between January 2008 and December 
2009.  The aims of this study are to estimate the incidence of CA-MRSA, identify clinical 
characteristics, risk factors, antibiotic susceptibility, and evaluate patient education in this 
specific population.    
 Epidemiologic studies examine differences in disease rates among populations in relation 
to age, gender, race, and differences in temporal or environmental conditions. In general, these 
studies can only identify patterns or trends in disease occurrence over time or in different 
geographical locations but cannot ascertain the causal agent or degree of exposure.  These 
studies are often very useful for generating hypotheses for further research.  
 Epidemiology is the quantitative study of the incidence and distribution of infectious 
diseases in the general population with the added goal of preventing and controlling the spread of 
these infections.  This study describes the incidence of CA-MRSA in SSTI that were cultured 
and also describes the characteristics of the disease, such as patient demographics, health-related 
characteristics, risk factors, and treatment within the specific population sampled in the primary 
care setting (Hulley, 2007). 
Strengths and Limitation of Proposed Design   
 One of the strengths of a descriptive study is that it gives the researcher an opportunity to 
collect data that describes the frequency of a condition though it does not study relationships.  
Descriptive studies can be invaluable in documenting the incidence, nature, and intensity of 
health-related conditions and behaviors and are critical in the development of effective 
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interventions (Polit, 2008).  This descriptive epidemiology study is the quantitative study of the 
incidence and distribution of an infectious disease in a specific clinical family practice.    
 The weaknesses of a descriptive study are that it can describe what seems to be a 
relationship but cannot support a prediction about cause and effect in how the relationship works, 
nor can cause and effect be tested with a descriptive study (Oman, 2003). 
Setting  
 The setting of the study is an outpatient primary care practice in Apopka, Florida.  The 
practice has a diverse group of patients that includes both children and adults who range in age 
from newborn to geriatric.  This practice sees on average approximately 75 patients a day.  
Ninety percent of these patients have either a private healthcare plan or Medicare, while the 
remaining 10% are uninsured.  The practice has one physician, one nurse practitioner, and one 
physician assistant.   
Sample 
Convenience sampling is utilized in this study for the ease of the researcher to access 
appropriate patients.  The medical records of patients diagnosed with a STTI and whose wounds 
were cultured and treated in a family practice in Apopka, Florida, serve as the sample size.  It is 
estimated that at least twelve patients are diagnosed with a skin and soft tissue infection per 
month.  This average was determined after creating a list of all patients seen between January 
2007 and December 2009 with a skin infection who were given a diagnosis that included the 
following:  boil, abscess, paronychia, pustule, insect/spider bite, pilonidal abscess, 
furuncle/carbuncle, cellulitis, impetigo, and folliculitis. 
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Strategies for Gaining Access to Medical Records 
The study design is based on a medical record review.  The medical records were 
obtained from existing patient populations within the practice that met the study inclusion and 
exclusion criteria.  After IRB approval, one more year was added to the study, which provided 
additional medical records for review in order to conduct a meaningful analysis.  
Exclusion Criteria 
1. Initial diagnosis and treatment of SSTI at another location other than family practice  
2. Patients with dental abscess 
3. Patients without documented wound culture laboratory reports 
4. History of hospitalization, admission into nursing home, skilled nursing facility, or 
hospice within the last 12 months 
5. Dialysis patient 
6. Iatrogenic high-risk invasive procedure in the previous three months 
7. Indwelling catheters or medical devices 
Inclusion Criteria 
1. Patient presenting with a cultured SSTI diagnosed as folliculitis, pustular lesions, boil, 
furuncle/carbuncle, abscess, “insect/spider bite,” cellulitis, paronychia, pilonidal abscess, 
impetigo 
2. Initial visit and treatment for SSTI at the family practice  
3. Laboratory wound culture and sensitivity report in the medical record   
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Institutional Review Approval 
Institutional Review Board approval was obtained before initiating this study.  
Permission was also obtained from the clinical administrator of the family practice.  For the 
purpose of this study, a waiver of consent was approved by the IRB as it met the criteria for a 
non-Food and Drug Administration regulated research (Department of Health and Human 
Services, 2005).  
HIPAA Guidelines and Confidentiality  
 The Health Insurance Portability and Accountability Act (HIPAA) form has been signed 
by all existing patients within the family practice and can be found in their medical records.  The 
investigator, as a provider in the practice, has authorization to review clinic records.  
 Strategies for protecting this information include coding research data, storing it in a 
secure location, protecting or destroying the key that identified participants, and limiting 
personnel who have access to identifiers.  The subject’s identifying information is kept in a 
separate log form and stored in a secure area with accessibility only to the principle investigator 
(see Appendix G). 
Study Instruments and Tools 
 For the purpose of this study, a data collection tool developed by the researcher to capture 
data to answer the research questions was used (see Appendix B).  The data tool was reviewed 




 A descriptive epidemiologic study involving patients with a skin and soft tissue infection 
who presented to Central Family Practice in Florida was conducted.  A medical record review of 
all patients who were diagnosed with an SSTI and wound culture obtained between the years of 
January 2007 to December 2009 were audited for the studies inclusion and exclusion criteria.  
The list of eligible participants that met the inclusion criteria was generated after reviewing 
laboratory logs that were kept within the practice that document all wound cultures obtained.  
The list was verified to not miss any potential participants by comparing reports received by 
three laboratory centers that service the practice.  The family practice has a specific account with 
each of these laboratories, and a report had been generated by each center of all wound cultures 
that were sent to them within the months of January 2007 to December 2009. 
 Information on demographic characteristics, clinical characteristics, potential risk factors, 
co-morbid conditions, clinical presentation, and treatments provided was collected by the 
investigator using a data collection tool and procedure form (see Appendix B).  A table was 
created that lists the variable codes; the SPSS label, the SPSS value, and measurement level for 
SPSS 16 (see Appendix A). 
Study Protocol/Procedures    
1. A list of eligible patients was compiled after reviewing the family practice laboratory log 
that documents all wound cultures obtained between the months of January 2007 to 
December 2009.  This was compared to the generated reports from the three laboratory 
centers to verify there were no missed potential participants. 
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2. All medical records of eligible patients were reviewed.  This was determined by the CPT 
code list generated from the billing department of patients who had a diagnosis of an 
SSTI between January 2007 and December 2009.    
3. Verification that a wound culture performed and that the laboratory reports, including 
antibiotic sensitivities, were available in the medical record. 
4. Investigator reviewed each medical record for inclusion and exclusion criteria to 
determine subject eligibility. 
5. Demographic information (age, gender, home location, ethnicity, insurance payer) was 
collected and documented on the data collection tool. 
6. Potential risk factors were collected and outlined on the data collection tool. 
7. Patient clinical characteristics (temperature, date onset of symptoms, and skin infection 
diagnosis) were collected and outlined on the data collection tool. 
8. Collect SSTI characteristics (purulent drainage present, incision and drainage performed, 
wound packing required, wound size, and antibiotic prescribed) as outlined on data 
collection tool. 
9. Microbiology reports were reviewed to determine the bacterial organism(s) identified on 
the wound culture and antibiotic susceptibilities and document as outlined on data 
collection tool to evaluate treatment. 
10. Documented if follow-up visits were recommended and whether they occurred; report 
any adverse events, including complications or hospitalizations. 
11. Reviewed and documented recurrent skin infections up to three months post initial 
infection.  
12. Reviewed and documented if patient was given wound care instructions. 
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13. Document all data on data collection tool. 
Data Collection Tool 
 Demographic, patient risk factors, clinical characteristics, SSTI wound characteristics, 
including culture and sensitivity report data, was captured and documented utilizing the data 
collection tool.  The tool was designed so that each variable being measured was assessed and 
coded for ease of entering into an SPSS statistical software file for data organization and analysis 
(see Appendix A). 
Data Analysis  
This section describes the statistics used to answer each research question and the 
rationale for the statistics chosen.  The data is analyzed using the SPSS 16.0 Windows statistical 
program (Chicago, Ill).  Six research questions were proposed: 
• Question One: What is the incidence of community-acquired MRSA in cultured skin and 
soft tissue infections in a suburban family practice setting in Apopka, Florida?  
• Question Two: What are the selected demographic associated with the culture positive 
CA-MRSA skin and soft tissue infections? 
• Question Three: What are the selected clinical characteristics associated with the culture 
positive CA-MRSA skin and soft tissue infections? 
• Question Four: What are the selected risk factors associated with the culture positive CA-
MRSA skin and soft tissue infections?   
• Question Five: What are the antibiotic susceptibilities associated with the culture positive 
CA-MRSA skin and soft tissue infections? 
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• Question Six: How many patients diagnosed with a SSTI had education regarding wound 
care documented in the medical record?  
This study is descriptive epidemiology retrospective study to report the incidence rate of 
CA-MRSA, identify patient demographics, clinical characteristics, and risk factors associated 
with culture positive CA-MRSA SSTIs, and, lastly, analyze antibiotic culture and sensitivity 
reports.  Descriptive statistics analyzed and summarized the patient risk factors, patient clinical 
characteristics, and SSTI wound characteristics.  The data was organized, explored, and 
described.  Any data identified as an out-of-range value, obvious error, miscoded data, and 
outlier was queried for accuracy and corrected.  Missing data was coded appropriately as to not 
skew statistical analysis.  Descriptive frequency was used to calculate frequency of distribution, 
measure of central tendency (mean, median, and mode), and dispersion shape of distributions.  
Measure of dispersion, such as variance and standard deviation was calculated.   
Limitations of the Study  
Several potential issues were identified that may be encountered with this proposed 
study.  The first issue is that only patients that had wound cultures done were included.  This 
likely introduces a selection bias as patients who had SSTIs that were not purulent or had not 
required an incision and drainage performed were potentially excluded.    
The second issue is that the patients’ medical and social histories are also limited by the 
retrospective design of the study.  The researcher is relying on the accuracy of documentation on 
the medical record by the providers or office staff.    
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The third issue is that the data collection questionnaire was developed specifically for 
purpose of this study.  The data collection tool has not been validated. The content, predictive, 





CHAPTER 4: RESULTS 
This chapter describes the sample and reports the results of the statistical analysis of the 
data collected to determine the incidence of CA-MRSA in a suburban family practice and 
describes associated demographic, clinical characteristics, risk factors, antibiotic susceptibility, 
and evaluate patient education.  The statistical computer program, SPSS 16.0, was used to 
analyze and evaluate the variables for the purpose of answering the research questions for this 
study:  
• Question One: What is the selected incidence of community-acquired MRSA in cultured 
skin and soft tissue infections in a suburban Florida family practice? 
• Question Two: What are the selected demographic characteristics associated with the 
culture positive CA-MRSA skin and soft tissue infections?  
• Question Three: What are the selected clinical characteristics associated with the culture 
positive CA-MRSA skin and soft tissue infections? 
• Question Four: What are the selected risk factors associated with the culture positive CA-
MRSA skin and soft tissue infections?   
• Question Five: What are the antibiotic susceptibilities associated with the culture positive 
CA-MRSA skin and soft tissue infections? 
• Question Six: How many patients diagnosed with a SSTI had education regarding wound 
care documented in their medical record? 
Description of the Sample 
An extensive review of the medical records in the practice between January 1, 1997 and 
December 31, 2009, was completed.  During that period, there were 225 medical records that had 
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some type of skin or soft tissue infection (SSTI).  Of those medical records, 62 met the inclusion 
and exclusion criteria for the study.  One hundred percent (100%) of the medical records 
documented that a wound culture had been completed, and the laboratory report describing 
antibiotic susceptibilities were available for review for each of these records.    
 Of the 62 wound cultures obtained, 71% (n=44) grew one or more organisms.  Of the 44 
culture positive samples that grew one or more organisms, 84% (n=37) were identified as 
Staphylococcal aureus. Other non-Staphylococcal isolates included gram- positive 7% (n=3), 
gram-negative organisms 5% (n=2), and other bacterial organisms 5% (n=2) (see Table 1).  Of 
note, 29% (n=18) of all wounds that were cultured showed no bacterial growth.  
 
Table 1. Characteristics of Isolated Organisms 
Organisms    Percent % 
(N=44)     
Staphylococcus aureus   84% (n=37) 
 MRSA 66% (n=29) 
 MSSA 18% (n=8) 
   
Non-staphylococcus aureus   16%   (n=7) 
 Gram positive 7% (n=3) 
 Gram negative 4.5% (n=2) 
 Other 4.5% (n=2) 
 
 
Further analysis of the 44 culture positive wounds revealed that the incidence of 
methicillin-resistant Staphylococcus aureus (MRSA) was 66% (n=29), while 18% (n=8) were 
methicillin-sensitive Staphylococcus aureus (MSSA).  
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Demographic characteristics of the patients’ medical records (n=29) that cultured positive 
CA-MRSA skin and soft tissue infection are shown in Table 2.  The mean age of those with CA-
MRSA was 40 years, with a range from 7 to 90 years.  Sixty-two percent (n=18) were male, and 
38% (n=11) were female; additionally, 69% (n=20) lived within a 10-mile radius from the family 
practice, while 31% (n=9) lived in a surrounding suburb.  The most common race was Caucasian 
at 83% (n=24), with African Americans totaling 10% (n=3) and Hispanics tallying 7% (n=2).  In 
regards to payor sources, a study of the medical records determined that 90% (n=26) had private 
insurance and 10% (n=3) were self-pay.  
 
Table 2. Demographics of Culture Positive SSTI CA-MRSA 
Variable   Frequency Percent 
(N=29)     
Age         
 <17 years old  4 14% 
 18-60 years old  24 80% 
 >61 years old  2 6% 
Gender         
 Male   18 62% 
 Female   11 38% 
Race         
 Caucasian  24 83% 
 African American  3 10% 
 Hispanic   2 7% 
Home Location       
 Apopka   20 69% 
 Orlando   1 3% 
 Other   8 27% 
Insurance          
 Yes   26 90% 




Clinical risk factors associated with culture positive CA-MRSA skin and soft tissue 
infections are summarized in Table 3.  The most common risk factors identified was obesity 41% 
(n=11), diabetes mellitus 24% (n=7), a MRSA infection within the previous 12 months 24% 
(n=7), and attending daycare or school 10% (n=3).  Other risk factors evaluated found that none 
of the positive culture CA-MRSA records had a history of illicit drug abuse or were immune-
compromised.  Additionally, only one medical record identified the presence of a chronic skin 
condition of psoriasis.   
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Table 3. Clinical Risk Factors Associated with Culture Positive CA-MRSA 
Variable   Frequency Percent 
Previous MRSA infection (n=29)   
 Yes   7 24% 
 No   22 76% 
Chronic skin condition 
(n=29)     
 Yes   1 3% 
 No   28 97% 
IV drug abuse 
(n=29)       
 Yes   0 0% 
 No   25 86% 
 Unknown  4 14% 
Attends day-care/school (n=29)   
 Yes   3 10% 
 No   26 90% 
Diabetes Mellitus (n=29)     
 Yes   7 24% 
 No   22 76% 
BMI 
(n=27)         
 <19   2 7% 
 19-29   14 52% 
 >30   11 41% 
Immune Compromised 
(n=29)     
 Yes   0 0% 
 No   29 100% 
 
 
Clinical characteristics associated with the culture positive SSTIs are displayed in Table 
4.  The majority 86% (n=25) of those infected with MRSA showed no presence of fever, having 
a temperature of <99 degrees Fahrenheit at the time of presentation.  The mean duration of 
symptoms at the time of presentation was 14 days, with a range from 3 to 60 days.  Most of the 
skin and soft tissue infections had purulent drainage 90% (n=26), with 79% (n=23) of the 
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wounds requiring an incision and drainage; additionally, only 3 (10%) required wound packing.  
The mean size of the studied skin and soft tissue infections was 3 centimeters, with a range of 1 
to 6 centimeters.  There were 55% (n=16)) of the medical records that lacked documentation of 
the skin and soft tissue infection size and 38% (n=11) missing day’s onset of symptoms.  There 
were four wound types identified for the skin and soft tissue infections, with the most common 
diagnosis being an abscess 62% (n=18).  Others included boils 24% (n=7), pustules 10% (n=3), 
and cellulitis 4% (n=1). 
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Table 4. Clinical Characteristics Associated with Culture Positive MRSA SSTI 
Variable  Frequency Percent  
      
Presence of Fever (n=29)   
 < 99˚ F  25 86%  
 99-101˚ F 0 0%  
 >101˚ F  1 4%  
 Unknown 3 10%  
SSTI Size, cm (n=23)   
 < 6 cm  21 91%  
 > 6 cm   2 9%  
Symptom Duration, d (n=18)   
 < 6 days  5 28%  
 6-14 days 7 39%  
 > 14 days 6 33%  
Purulent Drainage (n-29)   
 Yes  26 90%  
 No  3 10%  
Incision & Drainage (n=29)   
 Yes  23 79%  
 No  6 21%  
Wound Packed (n=29)   
 Yes  3 10%  
 No  26 90%  
SSTI Diagnosis 
(n=29)      
 Abscess  18 62%  
 Boil  7 24%  
 Pustule  3 10%  
 Cellulitis  1 3%  
  
 
Each of the skin and soft tissue infections that were culture-positive for CA-MRSA were 
prescribed a broad-spectrum antibiotic designed to eliminate the most likely suspected 
organisms.  The six antibiotics in this study show a variety of susceptibility and resistance 
features in regards to CA-MRSA that are displayed in Table 5.  Of these six, the most efficacious 
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ones were trimethoprim-sulfamethoxazole and doxycycline.  The CA-MRSA isolate were 
susceptible to trimethoprim-sulfamethoxazole 100% (n=29) of the time, while the susceptibility 
of doxycycline was 93% (n=27).  Clindamycin was the next most effective drug, successfully 
targeting CA-MRSA 65% (n=15) of the time; however, the organism was resistant to this 
medication 30% (n=7) of the time, while 4% (n=1) were intermediate.  Susceptibility and 
resistance testing for the drug rifampin was only done on 14 of the 29 wounds in these particular 
pathology records; however, the medication was 100% effective against CA-MRSA in 
combination with another antibiotic.  The last two antibiotics tested were cephalexin and 
erythromycin.  The results of both these antibiotics were identical in their ineffectiveness, in that 
93% (n=27) of the time the MRSA isolates were resistant to these medications.  
 
Table 5. Frequency of Susceptible Antibiogram Results in CA-MRSA Isolates 
Antibiotics     Susceptible Resistant Intermediate Not Done 
(N=29)               
Trimethoprim-sulfamethoxazole     29 (100%) 0% 0%  
        
Doxycycline   27 (93%) 1 (3.5%) 1 (3.5%)  
        
Clindamycin   15 (65%) 7 (31%) 1 (4%) 6 (21%) 
        
Cephelaxin    2 (7%) 27 (93%) 0%  
        
Rifampin    14 (48%) 0% 0% 15 (52%) 
        





In regards to patient education, wound care instructions were clearly documented in 45% 
(n=13) medical records. However, no documentation was found in 55% (n=16) of the records.   
Recurrence of infection in the clinical record was also assessed.  The review determined 
that of the 29 cases, 10% (n=3) developed recurrence of an SSTI three months after the initial 
diagnosis.  All of these patients had been treated with trimethoprim-sulfamethoxazole at their 
first presentation.  Also of note is that the organisms isolated in these three patients were 





CHAPTER 5: CONCLUSION 
In this chapter, the findings of the study as related to each research question regarding 
incidence of CA-MRSA, demographics, clinical characteristics, risk factors, antibiotic 
susceptibility, and patient education will be discussed.  Limitations of the study will be identified 
and study conclusions stated.  Finally, the implications for nursing practice and 
recommendations for future projects and research will be presented.   
Discussion 
With the recent trends toward increased incidence of MRSA in the general community, 
the number of patients presenting with SSTI treatment for CA-MRSA infections is becoming 
more common in ambulatory settings beyond the emergency department or specialty practices.  
In years past, uncomplicated skin and soft tissue infections were caused by methicillin-
susceptible Staphylococcus aureus (MSSA) and were effectively treated with beta-lactam 
antibiotics.  However, due to the rise in antibiotic resistance, this is no longer the case, even in 
healthy individuals (Moran et al., 2006).  Additionally, recent studies have concluded that Staph 
aureus incidence is higher in certain geographic locations with high poverty rates and 
community housing (Owens, 2009).  A review of the literature identified a need for further 
studies to be undertaken among different types of patients in a variety of different outpatient 
settings in order to confirm this alarming trend of increasing CA-MRSA.  This study was 
conducted at a suburban family practice in Florida for the purpose of determining the incidence 
of CA-MRSA SSTIs, as well as to identify relevant epidemiologic factors, antibiotic 
susceptibilities, and to evaluate patient education. 
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Incidence of CA-MRSA 
One of the major objectives for conducting this study was to determine the incidence of 
CA-MRSA of cultured SSTIs in a suburban Florida family practice.  The terms prevalence and 
incidence are often used interchangeably even though their definitions are distinct.  The patient 
population at risk included all patients that had some form of a positive STTI culture.  Cultures 
that yielded no growth were not analyzed, as this was taken to be a result of inadequate sampling 
or potentially a sterile wound (Bruce, 2008).  In this study, 71% of the SSTI cultures were 
positive for one or more bacterial organisms.  Based on microbiology resistance analysis, it was 
found that the incidence of CA-MRSA strains was 66%.  This incidence appears to be similar to 
the incidence reported by several previously cited studies.  In these three studies, the average 
incidence of MRSA found in a variety of SSTIs was calculated to be 73% (Jacobus, 2007; 
Kaplan, 2005; Magilner, 2008).  Based on this information, this study would suggest that the 
community served by this family practice is at moderately high risk for CA-MRSA SSTIs.  As a 
result, health care providers need to consider this bacterial pathogen in their treatment 
management and follow recommended clinical treatment guidelines.   
Demographic Characteristics of CA-MRSA SSTI 
There has been a lack of comprehensive epidemiological studies of patients infected with 
CA-MRSA in part due to CA-MRSA not being a reportable disease, unless associated with a 
community outbreak or death of a patient.  Outbreaks have occurred in several discrete patient 
populations.  Identified at-risk populations include children, soldiers, prisoners, homeless 
persons, intravenous drug users, and men who have sex with men (Gorwitz, Jernigan, Powers, 
Jernigan, & Participants in the CDC-Convened Experts' Meeting on Management of MRSA in 
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the Community, 2006).  In this study, the demographic characteristics evaluated included age, 
gender, ethnicity, place of residence, and health insurance coverage.  
Demographic characteristics of the culture positive CA-MRSA SSTI for this study 
demonstrated that males (62%) were infected more frequently than females (38%).  It has been 
reported in the literature, that risk of skin infection with CA-MRSA is higher in those involved in 
contact sports, sharing of personal items or sporting equipment.  Men tend to participate in these 
activities more frequently which are postulated as a possible reason why males were infected at a 
higher rate than women in this study.   The literature reports that children attending day care or 
school are at higher risk CA-MRSA SSTI (Hinckley & Allen, 2008; Hulten et al., 2006; 
Magilner, 2008; Purcell & Fergie, 2005).  However, in this study, the median age was 40 years 
old, with a total of only three (14%) pediatric patients under the age of 17 that had culture 
positive CA-MRSA.  This finding is not surprising for this practice, as pediatrics comprises less 
than 10% of the patient population.  The incidence of CA-MRSA has been also been reported in 
younger patients (Kowalski, Berbari, & Osmon, 2005).  In this study, 80% of the patients 
infected with CA-MRSA were between the ages of 18-60 years old.  This is an important 
finding, as much of the literature on CA-MRSA focuses on the pediatric patient.  This study 
clearly documents that adult patients are also at high-risk for CA-MRSA when presenting with 
SSTIs to suburban family practices.  Older patients greater than 60 years of age are not infected 
as commonly with CA-MRSA strains as are the young and the healthy.  It is postulated that this 
may be due to outbreaks primarily being reported in those who live in crowded conditions or 
have close physical contact with others (Kowalski et al., 2005).  It is important to note that if an 
elderly person living in a nursing home or assisted living facility contracts MRSA; it is classified 
as healthcare-associated versus a community-acquired infection.  Patients with risk factors that 
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fulfill these criteria include military personnel, prison inmates, athletes, IV drug users, and 
daycare centers.  Individuals in these areas are primarily young people less than 60 years of age.  
Certain ethnic groups have also been identified as populations at risk for outbreaks of CA-
MRSA; these include Pacific Islanders, Native Americans/Alaska Natives, and Pacific and 
Canadian Aboriginals (Centers for Disease Control and Prevention, 2006c).  The most common 
race identifying as positive for CA-MRSA in this study was Caucasians (83%), followed by 
African Americans (10%), and lastly Hispanics (7%).  These results are consistent with racial 
census reported for this geographic location in Florida ("Apopka Florida Census, and 
Community Profile," 2010).  These findings demonstrate that there are other ethnic groups at 
high risk for CA-MRSA other than those previously reported in the literature, and primary care 
providers need to appropriately treat this bacterial pathogen.  
  The majority of the medical records did document that 90% of the patients had some 
type of health insurance. Only 10% were uninsured and self-pay. This is a noteworthy finding 
because it is in contrast to what is usually reported; namely, that communities with higher 
poverty rates and no health insurance are generally considered to be at higher risk for CA-MRSA 
(Owens, 2009).  This study refutes the previous conclusion because most of the patients had 
insurance and yet the incidence of CA-MRSA SSTI was still significantly elevated.  As a result, 
clinicians need to be aware that there is still a high risk for CA-MRSA SSTIs even in patients 
from less impoverished communities.  To note, the family practice under study reported that 8 to 
10% of their patients were uninsured; thus, the sample may not have represented the lower 
poverty population in that community.    
Researchers studying MRSA have recommended that studies be done in different types of 
outpatient health care settings.  A gap identified in the literature review was studies of CA-
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MRSA specifically in suburban settings to include suburban family practices.  It was important 
that data collected is also reflective of this type of population.  Ninety-eight percent of the 
medical records in this study documented that the home location was either in the suburb where 
the family practice was located or a nearby suburban town.  Thus, the findings of this study do 
reflect a suburban community.    
Clinical Characteristics of CA-MRSA SSTI 
 It is important that health care providers are able to identify clinical characteristics 
associated with CA-MRSA, as these may help guide the practitioner in correctly diagnosing and 
treating skin and soft tissue infections that could have more serious consequences.  
Unfortunately, there are no clinical features that clearly distinguish CA-MRSA from MSSA skin 
infections.  The most common skin and soft tissue diagnosis in this study was an abscess.  Most 
patients presented with no fever and the wound size was less than five centimeters.  The only 
other significant difference noted was that CA-MRSA infections presented with less than six 
days’ duration of symptoms; in contrast, all of those with MSSA had symptom duration of six 
days or greater.  This finding is consistent with literature that reports that a typical CA-MRSA 
related SSTI can have the clinical characteristics of an acute abscess that can form almost 
overnight (Owens, 2009).  Yet, based on these findings, there is no reassurance that less severe 
SSTI’s are not also caused by CA-MRSA.  This statement is supported by two other cohort 
studies looking at the usefulness of clinical characteristics to help differentiate MRSA from 
MSSA infections.  The first, completed in 2002, was an observational study of 144 children.  The 
second was done in 2007 and enrolled 180 adult patients.  Both studies found no clear 
distinguishing hallmark features for MRSA (Miller, 2007; Sattler, 2002).   
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In regard to SSTI management, most CA-MRSA infections in this study were purulent 
and required an incision and drainage.  The majority of CA-MRSA infections were less than six 
centimeters in size, which could be why only a few required wound packing.  Incision and 
drainage continues to be a mainstay of treatment for a fluctuant abscess and is recommended by 
most infectious disease experts (Frazee, 2005; Gorwitz et al., 2006).  If clinicians are unsure 
whether pus is present in a lesion, an attempt can be made to aspirate fluid from the lesion using 
an adequate size needle and syringe (Centers for Disease Control and Prevention, 2006c).      
Risk Factors of CA-MRSA SSTI 
The only significant clinical risk factors associated with CA-MRSA found in this study 
was obesity (41%), BMI >30, a history of diabetes mellitus (24%), and a history of previous 
MRSA infection (24%).  These findings are consistent with risk factors that the CDC reports 
(Gorwitz et al., 2006).  This is important because clinicians need to consider prescribing an 
antibiotic that is effective against CA-MRSA to patients presenting with an SSTI who are 
diabetic, obese, or have had a previous MRSA infection...   
Antibiotic Susceptibilities of CA-MRSA SSTI Isolates 
Similar to previous reports in other studies, CA-MRSA isolates in this study were 
generally susceptible to trimethoprim-sulfamethoxazole (100%) and doxycycline (93%), both of 
which were prescribed for 10-day courses of treatment.  Trimethoprim-sulfamethoxazole and 
doxycycline are both Food and Drug Administration (FDA) approved for the treatment of SSTIs 
caused by Staph aureus but not specifically for MRSA isolate infections (Gorwitz et al., 2006).  
However, Lyer and Jones (2004) reported successful use of trimethoprim-sulfamethoxazole 
along with incision and drainage of abscesses for the treatment of CA-MRSA.  In a small case 
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report, doxycycline and minocycline, which are both long-acting tetracycline class antibiotics, 
were successfully used in treating tetracycline-susceptible MRSA isolate SSTIs (Ruhe, 2005).   
On the other hand, in this study, clindamycin resulted in 24% resistance.  This supports experts’ 
recommendations of avoiding empirical therapy with clindamycin when local rates of 
clindamycin resistance exceed 10-15% among MRSA isolates causing skin and soft tissue 
infections cite (Kaplan, 2005).   
In this study resistance to cephelaxin (93%) and erythromycin (93%) was similar to 
results reported in the literature, and along with beta-lactam antibiotics should be avoided in the 
treatment of suspected MRSA SSTI (Centers for Disease Control and Prevention, 2006c).  This 
study identified that rifampin was susceptible only 48% of the time; because of this, it is 
recommended that rifampin primarily be prescribed in combination with another antibiotic 
known to be effective against CA-MRSA isolates.  There have been studies conducted that 
support this finding.  One such study found that when rifampin was given alone, resistance 
rapidly developed unless prescribed in combination with other antibiotics to which the isolate is 
susceptible (Iyer, 2004).  A second study found that there is little data available supporting the 
incremental benefit of adding rifampin to the course of antibiotic therapy (Hinckley & Allen, 
2008).  However, an additional study suggested that a theoretical benefit may be derived from 
the high concentration level of rifampin achieved in mucosal surfaces, promoting eradication of 
MRSA isolate carriage  (Simor et al., 2007).   
Clinical guidelines for options for empiric outpatient antimicrobial treatment of SSTIs 
when MRSA is a consideration have been created and supported by the CDC, AMA and ISDA 
organizations as previously discussed in chapter 2 (Figure 2).  The findings of this study suggest 
that the family practice under study did adhere to the recommendations and consistently were 
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prescribing appropriate empiric antibiotics.  The CPG also recommends that fluctuant SSTI with 
purulent drainage have an incision and drainage performed.  Again, the site under study did 
regularly perform this procedure when appropriate.  Unfortunately, there was no consistency in 
obtaining wound cultures, as evidenced by the medical record review.  Of the 225 charts initially 
identified, only 62 met the inclusion and exclusion criteria mostly because a culture was not 
performed.  The practice does not follow any specific CPG, which is probably why this variation 
exists.  
 Patient Education and Documentation 
In addition to empiric antibiotic therapy, wound care education is critical to the 
management plan of SSTIs.  This study found that 55% of the medical records lacked 
documentation that wound care instruction had been given to the patient.  Fortunately, only three 
reported recurrent SSTIs cases occurred, of which only one of those cases had no wound care 
instruction documented.  Despite this, patient education is considered an essential component of 
SSTI therapy, especially in regards to the strategies of adequate hygiene, hand washing, and 
cleaning and covering wounds.  These standard infection control precautions are the most 
important methods for primary prevention and transmission reduction of MRSA.  To that end, 
the CDC provides an informative handout titled “MRSA Information for Patients, which is 
available http://www.cdc.gov/ncidod/dhqp/pdf/ar/MRSAPatientInfoSheet.pdfat.  
Limitations of Study 
 There are several limitations to this study that must be considered.  Firstly, the study was 
a retrospective medical record review.  Thus, the points of concern were limited by how well the 
provider and staff had documented the answers to the variables being studied.   
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Secondly, the search for records was based on the International Classification of Diseases 
(9th
 Thirdly, there exists the possibility of selection biases in regards to which SSTIs were 
cultured, therefore skewing the results.  It is possible that assumptions about the SSTI location, 
size, and duration of symptoms may have influenced the provider as to whether to culture or not.  
Clinical practice guidelines are systematically developed statements to assist practitioners with 
patient decisions about appropriate healthcare for specific clinical circumstances.  Their 
successful implementation should improve quality of care by decreasing inappropriate variation 
in treatment.  Unfortunately, despite the dissemination of clinical guidelines for MRSA, their 
effect on changing clinicians’ practice behavior has been limited (Borry, 2006).  The clinical 
guideline outlined in Figure 1 recommends that purulent lesions be cultured for susceptibility 
testing.  In this study, there were medical records reviewed that met the inclusion criteria for a 
SSTI diagnosis but were excluded because a wound culture was not performed.  As a result, this 
study sample size was smaller than expected and suggests that there was no consistent method or 
the clinical guideline routinely followed.   
 Revision, Clinical Modification) codes for the diagnoses of abscess, boil, pustule, cellulitis, 
impetigo, furuncle/carbuncle, paronychia, insect/spider bite, pilonidal abscess, and the procedure 
code for incision and drainage and wound cultures collected within 24 hours of diagnosis.  
Patients who presented with an abscess that was drained and cultured may have been missed if 
any of the above were not included in their coding. 
The fourth possible limitation is that in the suburban town studied, there are several other 
family practices as well as a hospital; because of this, many individuals with CA-MRSA skin 
infections are likely to have presented to other practices or to the emergency room.  This could 
mean that the sample size of this study is not large enough to draw significant conclusions about 
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the population at large.  Also, because less than 10% of this family practice’s population was 
pediatric patients, this study is limited in its ability to make generalizations of the results to this 
specific population. 
 Finally, this study was limited only to those SSTIs in which a wound-site culture was 
obtained.  Conclusions from this study, therefore, should not be extrapolated to all SSTIs but 
must be limited to those patients presenting to a family practice with culturable skin infections. 
Conclusion 
The result of this study suggests similar incidence of CA-MRSA (66%) in cultured SSTIs 
presenting to this suburban family practice in Florida as compared to incidences found in the 
literature.  Because of this, it is imperative that practitioners adopt evidence-based medicine into 
their practice in order to effectively treat this problem.  The results of this study do support a 
policy change within the practice for the management of SSTI.      
The policy change includes the integration of a clinical guideline for the management of 
CA-MRSA SSTI within the practice.  The CDC, AMA, and IDSA have jointly developed a 
treatment algorithm guideline for the management of SSTI’s (Figure 1).  This guideline 
recommends that all purulent and/or incision and drained SSTIs be cultured for the purpose of 
antibiotic susceptibility testing and surveillance.  Implementing this clinical guideline should 
improve patient outcomes, which is a primary goal of this practices clinicians.     
In this study, over half of the medical records were lacking wound care documentation.  
To address this issue, the practice will incorporate into its medical record templates an area to 
document wound care instructions.  Patients will also be given an educational pamphlet created 
by the CDC aimed at explaining what a MRSA infection is.  This pamphlet also educates the 
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importance of hygiene, such as hand washing, cleaning, and covering of wounds to reduce the 
potential spread of this infection (Appendix H).  
 Only as research on CA-MRSA continues, with particular emphasis on standardizing 
treatment protocols for wound culturing, will clinicians be able to improve surveillance, increase 
tracking of incidence and strengthen current clinical treatment guidelines. 
Lastly, the judicious use of antibiotics cannot only provide definitive cure but is also 
critical in the prevention of antibiotic resistance.  Antibiotic susceptibility testing confirmed that 
those therapies provided in this study were consistent with CDC recommendations for 
appropriate empiric antibiotic treatment for suspected CA-MRSA; that is, trimethoprim-
sulfamethoxazole and doxycycline.  Practitioners should avoid beta-lactam, cephelaxin, and 
erythromycin as these have been found to be ineffective against MRSA.   
Implications for Nursing Practice  
  The rapid emergence of CA-MRSA has had an impact on all health care providers, and as 
the incidence rises in the outpatient setting, it has become a significant burden to society.  These 
SSTI infections may appear relatively minor at first but can lead to life-threatening lung, heart, 
and bloodstream infections if not managed properly.  Health care providers need to obtain 
specimens for culture and sensitivity testing and then direct their treatment according to 
generally known microbial susceptibility, especially in clinical situations where empirical 
therapy is initiated at first patient presentation.  It is imperative that health care providers 
understand the importance of the judicious use of antibiotics for the prevention of antibiotic 
resistance.  The National Institute of Allergy and Infectious Diseases formulated a strategy 
directed at reducing those factors that contribute to antimicrobial drug resistance (Peters, 2008).   
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Only by obtaining wound cultures will proper tracking and surveillance of CA-MRSA infections 
be better understood.  A genetic distinction between CA-MRSA and HA-MRSA has been 
identified which affects treatment options.  This genetic distinction indicates that HA-MRSA is 
not the same bacteria that cause CA-MRSA SSTIs.  Community-acquired MRSA is often 
susceptible to many non-beta-lactam antibiotics, where as HA-MRSA is typically resistant to 
these antibiotics.  Having made distinction, the CDC has defined different criteria to properly  
identify, diagnose, treat, and prevent the spread, and invasiveness of both CA-MRSA and HA-
MRSA infections (Center for Disease Control and Prevention, 2007a).  Nurse practitioners are 
positioned to be leaders in disease prevention and treatment in the community, as well as strong 
influences in the lives of our patients through the education we provide our patients regarding the 
risk factors for CA-MRSA. 
Implications for Education 
 Standard infection control precautions are the most important methods for prevention of 
transmission of MRSA.  It is imperative that patients understand what MRSA is, who is at risk, 
the seriousness of this infection, and how to properly treat and keep from spreading this 
infectious bacterium.  The CDC has created patient educational tools about CA-MRSA and has 
made them available online at:  http://www.cdc.gov/ncidod/dhqp/ar_mrsa.html. These tools 
emphasize proper hand washing, good personal hygiene, contact precautions, and proper wound 
care. 
It is also important that health care providers to stay abreast with continuing education on 
CA-MRSA.   The incidence of resistant bacteria microorganisms has increased in this country 
and is now a serious public health problem.  Nurse practitioners need to examine the evidence 
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and incorporate the findings into their practice as they manage and treat patients with SSTIs. 
There is a wealth of information available at the CDC website for health care providers for the 
purpose of keeping abreast of the latest research and recommendations for treatment.  
Recommendations for Future Research  
More clinical studies are warranted in primary care settings in order to better understand 
the incidence of CA-MRSA in variety of communities.  Future research could include 
randomized controlled trials (RCT) of the use of antibiotics after drainage of abscesses on SSTI 
that are less than five centimeters versus five centimeters or greater; as well as randomized trials 
to determine whether packing an abscess with gauze improves wound outcomes or speed of 







APPENDIX A: SPSS VARIABLE KEY CODE 
  
53 
SPSS Key Code 1 
Variable Codes SPSS Label SPSS Value(s) Measurement Level 
 
Age Age group Enter Age Scale 
Gender Gender 1 = Male 
2 = Female 
Nominal 
Home Location Home 1 = Apopka 
2 = Orlando 
3 = Longwood 
4 = Mount Dora 
5 = Tavares 
6 = Clermont 
7 = Maitland 
8 = Other 
Nominal 
Ethnicity Race/Ethnicity 1 = Hispanic 
2 = Black 
3 = White 
4 = Asian 
5 = Other 
Nominal 
Medical Insurance Insurance 1 = Private 
2 = Medicare 
3 = Medicaid 
4 = Self-pay 
5 = Other 
Nominal 
Risk Factor #1 Previous MRSA 1 = Yes 
2 = No 
Nominal 
Risk Factor #2 Chronic skin condition – 
eczema or psoriasis 
1 = Yes 
2 = No 
Nominal 
Risk Factor #3  IV drug use 1 = Yes 
2 = No 
Nominal 
Risk Factor #4 Attends daycare/school 1 = Yes 
2 = No 
3 = Home school 
Nominal 
Risk Factor #5 Diabetes mellitus 1 = Yes 
2 = No 
Nominal 
Risk Factor #6 Obesity – BMI >30 1 = Yes 
2 = No 
Nominal 
Risk Factor #7 Immune compromised 1 = Yes 




Temperature (in Fahrenheit)  1 = < 99 
2 = 99-101 




BMI 1 = Equal or <18 
2 = 19-29 




Days symptoms present 
before presentation 
Enter days  Scale 
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Variable Codes SPSS Label SPSS Value(s) Measurement Level 
 
Clinical 
characteristic #4  
SSTI Diagnosis 1  = Boil 
2  = Abscess 
3  = Paronychia 
4  = Pustular Lesion 
5  = Insect/spider bite 
6  = Pilonidal abscess 
7  = Furuncle/carbuncle 
8  = Cellulitis 




Purulent drainage 1 = Yes 




I&D performed 1 = Yes 




Wound packing 1 =Yes 






1 = <5 cm 




Antibiotic 1 = Septra 
2 = Doxycyline 
3 = Clindamycin 
4 = Keflex 
5 = Erythromycin 
6= Rifampin 
7= Bactroban 
8 = Other  
Nominal 
Wound culture Bacterial Pathogen type 1 = MRSA 
2 = MSSA 
3 = Other Gm positive 
4 = Other Gm negative 
5 = Other organism 
6 = No growth 
Nominal 
Antibiotic 
susceptibility  #1 
Septra 1 = Susceptible 
2 = Resistant 
3 = Intermediate 
4 = N/A 




Doxycycline 1 = Susceptible 
2 = Resistant 
3 = Intermediate 




Clindamycin 1 = Susceptible 
2 = Resistant 
3 = Intermediate 




Keflex 1 = Susceptible 
2 = Resistant 




Variable Codes SPSS Label SPSS Value(s) Measurement Level 
 
4 = Not done 
Antibiotic 
susceptibility #5 
Erythromycin 1 = Susceptible 
2 = Resistant 
3 =Intermediate 




Rifampin 1 = Susceptible 
2 = Resistant 
3 = Intermediate 




Bactroban 1 = Susceptible 
2 = Resistant 
3 = Intermediate 




A.E.  1 = Complications 
2 = Hospitalizations 
3 = None 
Nominal 
Patient education 
on wound care 
Wound instructions 
documented 
1 = Yes 




Recurrent SSTI 1 = Yes 











DATA SHEET 1:  COLLECTION TOOL 
Medical Record Review 
 
Date: _______________ Subject # _____________________ Study site: ______________ 
 
Exclusion Criteria
1. Initial diagnosis and treatment of SSTI at another location  
: (If any answers yes = do not enroll patient) 
other than family practice.      ___Yes ___No 
2. Patients with dental abscess      ___Yes ___No 
3. Patients without documented wound culture reports   ___Yes ___No 
4. History of hospitalization, admission into nursing home,  
skilled nursing facility or hospice within the last 12 months  ___Yes ___No 
5. Dialysis patient.       ___Yes ___No 
6. Iatrogenic high risk invasive procedure in the previous 3 months ___Yes ___No 
7. Indwelling catheters or medical devices    ___Yes ___No 
 
Inclusion Criteria
1. Patient presenting with SSTI diagnosed as folliculitis, pustular lesions, boil, 
furuncle/carbuncle, abscess, “insect/spider bite”, cellulitis, paronychia, pilonidal abscess, 
impetigo.        ___Yes ___No 
:       (If any answers no, do not enroll patient)  
2.  Initial visit and treatment for SSTI at Central Family Practice. ___Yes ___No 
3. A wound culture obtained.      ___Yes ___No 
 
 
SECTION 1 – DEMOGRAPHIC INFORMATION (1-6) 
Age:  _________
 
 yr old. Gender: (1) Male   (2) Female   
DOB: _____________  
  
Home Location: (1) Apopka ___ (2) Orlando___ (3) Longwood___ (4) Mount Dora___ 
 (5) Tavares____ (6) Clermont__ (7) Maitland____ (8) Other ___  
 
Race/Ethnicity: (1) Hispanic ____ (
 
2) Black   (3) White   (4) Asian   (5) Other   
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Insurance payer: (1) Private  (2) Medicare  (3) Medicaid  (4) Self-Pay  (5) Other  
 
 
 SECTION 2 – PATIENT RISK FACTORS (1-8)  
 
1. Diagnosed with MRSA within the past 12 months.  (1) Yes ___ (2) No ___ (3) Unknown 
2. Chronic skin conditions (eczema or psoriasis)  (1) Yes ___ (2) No ___ (3) Unknown 
3. Use of IV street drugs.     (1) Yes ___ (2) No ___ (3) Unknown 
4. Attends a child care center or school?   (1) Yes __   (2) No ___ (3) Unknown 
5. Diabetes Mellitus      (1) Yes ___ (2) No___ (3) Unknown 
6. Obesity (BMI>30)      (1) Yes ___ (2)No  ___ (3) Unknown 
7. Immune compromised in the last 12 months   (1) Yes ___ (2) No ___ (3) Unknown 
(HIV, IV drug abuse, active Hepatitis C or receiving chemotherapy agents).  
 
SECTION 3 – Patient Clinical Characteristics   
 
Oral Temperature (Fahrenheit)   ___ (1) < 99   ___ (2) 99-101   ___ (3) > 101   BMI______ 
         
Date onset of symptoms (Day(s):   (length of symptoms before presentation) 
 
Skin infection diagnosis: 
  (1) Boil   (4) Pustular lesion   (7) Furuncle/carbuncle 
  (2) Abscess   (5) Insect/spider bite   (8) Cellulitis 
  (3)Paronychia   (6) Pilonidal abscess   (9) Impetigo   (10) Folliculitis 
Wound Description:        
 
Purulent drainage present? (1)Yes   (2) No   
 
Incision & Drainage performed? (1)Yes   (2) No   
 
Wound Packed? (1) Yes   (2) No   
  
Wound measurement (estimate): Length   Width   Depth   
  
Antibiotic prescribed:   
  (1) Septra   (2) Doxycyline   (3) Clindamycin   (4) Keflex 




SECTION 4:  Culture and Sensitivity Report Date:   
Visit 1- wound culture result:  
 
List pathogen(s)   (1) MRSA 
   (2) MSSA 
   (3) Other Gram positive bacteria 
   (4) Other Gram negative bacteria 
  (5) Other:   
   (6) No growth 
 
Antimicrobials Susceptibility: 
(1)Susceptible (2) Resistant (3) Not available (4) Not done 
(1) Septra (TMP-SMX)         
(2) Doxycycline         
(3) Clindamycin         
(4) Keflex ____ ____ ____ ____ 
(5) Erythromycin ____ ____ ____ ____ 
(6) Rifampin ____ ____ ____ ____ 
(7) Bactroban ____ ____ ____ ____ 
(8) Other ____ ____ ____ ____ 
 
 
SECTION 5:   




Patient education documented regarding wound care. (1)Yes     (2) No   
 
Recurrent SSTI 3 months after treatment.   (1)Yes   (2) No   
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Disease          AMA     IDSA  Centers for 
 Control and Prevention AMERICAN   M E D I C A L ASSOCIATION  Infectious Diseases Society of America 
 
SDA: 07-0827: PDF: 10/07: f 
 
 
           
 
CDC 
† For severe infections requiring inpatient 
management, consider consulting infectious 
disease specialists. 
‡ Visit www.cdc.gov/mrsa for more info. 
 
Abbreviations: 
I & D – incision and drainage 
MRSA – methicillin-resistant S. aureus 
SSTI – skin and soft tissue infection 
Patient presents with 





 Complaint of “spider 
bite” 
Possible cellulitis without 
abscess: 
 Provide antimicrobial 
therapy with coverage 
for streptococcus spp. 
 Maintain close follow-up 
 Consider adding 
coverage for MRSA (if 
not provided initially), if 
patient does not 
respond. 
Is lesion purulent (i.e., are any of 
the following signs present)? 
 Fluctulance-palpable fluid-
filled cavity, movable, 
compressible 
 Yellow or white center 
 Central point or “head” 
 Draining pus 
 Possible to aspirate pus 
with needle and syringe 
1. Drain the lesion- very important! 
2. Send wound drainage for culture and susceptibility testing 
3. Advise patient on wound care and hygiene (see patient 
education pamphlet) 
4. Discuss follow-up plan with patient 
 
-Consider antimicrobial therapy with 
coverage for MRSA in addition to I&D 
    
-See table for empiric outpatient microbial 
treatment options (see Figure 2) → 
OUTPATIENT† MANAGEMENT OF SKIN AND SOFT TISSUE 
INFECTIONS IN THE ERA OF COMMUNITY-ASSOCIATED MRSA‡ 
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APPENDIX D: OPTIONS FOR EMPIRIC OUTPATIENT ANTIMICROBIAL 









Dose:  450 mg tid po x 10 
days 
 FDA-approved to treat 
serious infections due to 
S. aureus 
 D-zone test should be 






associated disease, while 
uncommon, may occur 
more frequently in 
association with 








100 mg bid po x 10 
days 
 Doxycycline is FDA-
approved to treat S. 
aureus skin infections. 
 
 Not recommended during 
pregnancy. 
 Not recommended for 
children under the age of 
8. 
 Activity against group A 
streptococcus, a common 





Dose:  TMP/SMX DS – 1 
po bid x 10      days 
 
 
 Not FDA-approved to 
treat any staphylococcal 
infection 
 May not provide coverage 
for group A 
streptococcus, a common 
cause of cellulitis 
 Not recommended for 
women in the third 
trimester of pregnancy. 
 Not recommended for 




Dose:  300 mg bid po to 
add to TMP/SMX or doxy 
for synergy 
 
 Use only in 
combination with other 
agents. 




Dose:  600 mg po bid for 
10 days 
  
 Consultation with an 
infectious disease 
specialist is suggested. 
 FDA-approved to treat 
complicated skin 
 Has been associated with 
myelosuppresion, 
neuropathy and lactic 









those caused by MRSA. 
 MRSA is resistant to all currently available beta-lactam agents (penicillins and 
cephalosporins) 
 Fluoroquinolones (e.g., ciprofloxacin, levofloxacin) and macrolides (erythromycin, 
clarithromycin, and azithromycin) are not optimal for treatment of MRSA SSTIs because 
of resistance is common or may develop rapidly. 
* Data from controlled clinical trials are needed to establish the comparative efficacy of 
these agents in treating MRSA SSTIs.  Patients with signs and symptoms of severe illness 
should be treated as inpatients. 
** Consult product labeling for a complete list of potential adverse effects associated 
with each agent. 
Role of decolonization Regimens intended to eliminate MRSA colonization should not 
be used in patients with active infections.  Decolonization regimens may have a role in 
preventing recurrent infections, but more data are needed to establish their efficacy and to 
identify optimal regimens for use in community settings.  After treating active infections 
and reinforcing hygiene and appropriate wound care, consider consultation with an 
infectious disease specialist regarding use of decolonization when there are recurrent 
infections in an individual patient or members of a household. 
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Code Patient Risk Level 
0 General; not specified 
1 Pediatric 
2 Adults 
Code Care Setting 
1 General; not specified 
2 Community/outpatient centers/E.D. 
3 Hospital 
4 Long Term Care 
5 Laboratory Centers 
6 Centers for Disease Control/Government Agency 
Code Topics Presented 
1 CA-MRSA 
2 HA-MRSA 
3 Skin & Soft Tissue Infection (SSTI) 
4 Epidemiology (Prevalence, Incidence, Risk Factors, Co-morbidity, etc.) 
5 Antibiotics/Antibiotic Resistance 
6 Clinical Guidelines 
7 Cost/Economics 




11 Wound Culture/Microbiology 













Office Visit Date 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








Have you been diagnosed with a 
Staphylococcus aureus or MRSA infection? 
Below are answers to some common question... 
 
What is Staphylococcus aureus or Staph? 
Staph is a type of bacteria.  It may cause skin infections that look like pimples or boils.  Skin 
infections caused by Staph may be red, swollen, painful, or have pus or other drainage.  Some 
Staph (known as Methicillin-Resistant Staphylococcus aureus or MRSA) is resistant to certain 
antibiotics, making it harder to treat.  The information on this page applies to both Staph and 
MRSA. 
Who gets Staph infections? 
Anyone can get Staph infections.  People are more likely to get a Staph infection if they have: 
• Skin-to-skin contact with someone who has a Staph infection 
• Contact with items and surfaces that have Staph on them 
• Openings in their skin such and cuts or scrapes 
• Crowded living conditions 
• Poor hygiene 
How serious are Staph infections? 
Most Staph skin infections are minor and may be easily treated.  Staph also may cause more 
serious infections, such as infections of the bloodstream, surgical sites, or pneumonia.  
Sometimes, a Staph infection that starts as a skin infection may worsen.  It is important to 
contact your doctor if your infection does not get better. 
 
How are Staph infections treated? 
Treatment for a Staph skin infection may include taking an antibiotic or having a doctor drain the 
infection.  If you are given an antibiotic, be sure to take all of the doses, even if the infection is 
getting better, unless your doctor tells you to stop taking it.  Do not share antibiotics with other 
people or save them to use later. 
 
How do I keep Staph infections from spreading? 
• Wash your hands often or use an alcohol-based hand sanitizer 
• Keep your cuts and scrapes clean and cover them with bandages 
• Do not touch other people’s cuts or bandages 
• Do not share personal items like towels, razors, or toothbrushes 
• Do not work out at public gyms. School children should avoid contact sports 
• Avoid personal care services such as haircut, manicure, or massages 
           
If you have any questions about your conditions,     
please ask your doctor. For more information, please visit:   
http://www.cdc.gov/ncidod/dhqp/ar_mrsa.html.       Centers for Disease 
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